"The approval of lecanemab is a milestone moment but the decision by NICE not to approve it for the NHS is deeply disappointing," said David Thomas, head of policy at Alzheimer's Research UK.
"Lecanemab provides on average four to six months' slowing in the rate of progression from mild to moderate Alzheimer's disease, but this is just not enough benefit to justify the additional cost to the NHS," said Helen Knight, director of medicines evaluation at NICE.
"Dr. Samantha Roberts, chief executive of NICE, said the body had rigorously evaluated the available evidence, including the benefit for carers, but could only recommend treatments that 'offer good value to the taxpayer.'"
[
Collection
]
[
|
...
]